DEINOVE Announces Its Intention to Raise Funds to Maintain Its Development Momentum

Regulatory News:

Not to be published, transmitted or distributed, directly or indirectly, in the United States of America, Canada, Japan or Australia

DEINOVE (Paris:ALDEI) (Alternext Paris: ALDEI), a cleantech company that designs and develops a new generation of industrial processes based on the exploitation of Deinococcus bacteria, announces its intention to raise funds up to a maximum of about 25 million euros to capitalize on the technological innovation driven by DEINOVE and the proven capacities of its Deinococcus bacteria to create value.

"The progress made in recent months in terms of producing cellulosic ethanol with Deinococcus bacteria (see the press release of 16 January 2014) has stepped up the development of specialty chemicals through the use of different bacterial strains, in line with their performances. These compounds, obtained with our exclusive bioproduction process, provide us with many opportunities, notably within chemistry, fragrances, cosmetics and animal feed. Optimization of our DEINOL process is being pursued positively, which leads us to believe that our current results are just the tip of the iceberg in terms of what we can do in green chemistry!” said Emmanuel Petiot, CEO of DEINOVE.

Consequently, DEINOVE would like to invest the funds that would be raised to upgrade its technological platform, develop additional molecules within its DEINOCHEM program and perform the tests of various lignocellulosic raw materials required under its current and future partnerships.

These funds could be raised through a capital increase to be undertaken soon, subject to market conditions.

The Company also intends to request the transfer of its shares to the regulated market of Euronext Paris in order to take advantage of greater visibility in the international investment community, in line with its development stage and its potential markets.

ABOUT DEINOVE

DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the Deinococci. Taking advantage of the bacteria’s unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro-factories" to produce high value-added products from non-food biomass. The Company’s primary markets are 2nd-generation biofuels (DEINOL) and bio-based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally.

Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs over 40 people in its new offices and laboratories located in Montpellier, France.

More information at www.deinove.com, in particular on the two other press releases published on this day

WARNING

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to purchase the securities of DEINOVE.

The release, publication or distribution of this press release may be restricted in certain countries by applicable laws and regulations. Persons who are physically located in those jurisdictions and in which this press release is released, published or distributed must inform themselves about and observe such restrictions.

This announcement is an advertisement and not a prospectus within the meaning of the Prospectus Directive.

In France, shares of DEINOVE may be offered to the public only under a prospectus which will have received the visa of the Autorité des marchés financiers.

This document does not constitute an offer to sell, or a solicitation of offers to purchase or subscribe for, securities in the United States. The securities referred to herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. DEINOVE does not intend to register any portion of the proposed offering in the United States or to conduct a public offering in the United States.

With respect to each Member State of the European Economic Area other than France which has implemented Directive 2003/71/EC of the European Parliament and the Council of November 4, 2003 and, as the case may be, amendments thereto (the "Prospectus Directive”), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring from DEINOVE the publication of a prospectus in any Member State (other than France). As a result, the securities may not be offered and will not be offered in any Member States (other than France), except in accordance with the exemptions provided under article 3(2) of the Prospectus Directive, if they have been implemented in the relevant Member State(s) or in other cases circumstances which do not require the publication by DEINOVE of a prospectus under the Prospectus Directive and/or the laws and regulations applicable in these Member States.

This document does not contain or constitute an invitation, inducement or solicitation to invest. This press release is directed only at and is for distribution only to persons who (i) are outside the United Kingdom, (ii) are "investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order”), (iii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.”) of the Order or (iv) are other persons to whom an invitation or inducement to engage in investment activity (within the meaning of the Financial Services and Markets Act 2000) in connection with the issue or sale of any shares may otherwise lawfully be communicated or caused to be communicated (all such persons in (i), (ii), (iii) and (iv) together being referred to as "Relevant Persons”). This must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This press release is not, and may not be, distributed or sent, directly or indirectly, in the United States of America, in Canada, in Japan or in Australia.